ApconiX is delighted to welcome Dr Russell Huby to the team. Russell joins the team of experts in nonclinical safety toxicology at ApconiX and will be primarily working in the area of target safety assessments.
Russell graduated from the University of Oxford with a bachelor’s degree in biochemistry before going on to gain a PhD at the Royal Postgraduate Medical School (RPMS) at Hammersmith Hospital. He worked as a research fellow at the RPMS, the Imperial Cancer Research Fund and the MRC National Institute for Medical Research before joining AstraZeneca.
A former Associate Director of Molecular Toxicology at AstraZeneca, Russell’s career spans over 20 years in the pharmaceutical industry, 10 years in academia, and 3 years in medical communications. His extensive toxicology knowledge includes specialist expertise in oncology and in discovery project toxicology. Through working as both a project toxicologist and investigative scientist, Russell is a pragmatic problem-solver with an eye for the possible and the practicable.
“I am looking forward to working with team at ApconiX and bringing my own skills as an experienced biologist with expertise in toxicology, oncology, immunology and immuno-oncology”, commented Russell.
Professor Ruth Roberts added, “We are very excited to have Russell on board. With such an extensive experience of toxicology, he is a real asset particularly for target safety evaluations. It is vital to understand the potential unintended consequences of target modulation and Target Safety Reports form a key part of risk assessment and risk mitigation plans in drug discovery and development.”